BioSpace News Archive

Theravance Biopharma, Inc. (NASDAQ: TBPH)today announced the closing of a private placement of $400 million of non-recourse Triple II 9.5% fixed rate term notes.

Series B Proceeds will Advance XTX201 (Tumor-Selective IL-2) and XTX101 (Tumor-Selective aCTLA4) into the Clinic while Expanding Xilio’s Tumor-Selective Cytokine Pipeline

Three-year deal will enable broader chemical exploration and accelerate advanced molecular modeling across internal and collaborative programs

Company has formed a new Division, led by Dr. Cyril Empig, to develop a multi-modal approach to treating the COVID-19 and future emergent zoonotic outbreaks

VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, March 19 at 8:30am Eastern Time to report fourth quarter and year ended December 31, 2019 financial results and to provide a corporate update.

Stryker announced that Preston Wells will be appointed Vice President, Investor Relations and report to Glenn Boehnlein, the company’s Chief Financial Officer, effective June 1, 2020.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at two upcoming investor conferences.

Sema4, a patient-centered health intelligence company, and VieCure, an artificial intelligence (AI) informatics company with a leading point-of-care clinical decision support platform and a comprehensive electronic medical record (EMR) in oncology, today announced a strategic collaboration designed to help oncologists deliver personalized care and treatment to their patients.

Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results in the Journal of Urology

Seattle Genetics Announces Cancellation of Presentation and Webcast at the Cowen 40 th Annual Healthcare Conference